MedPath

Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)

Phase 2
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: LY041001 (HIIP)
Registration Number
NCT00099515
Lead Sponsor
Eli Lilly and Company
Brief Summary

The purpose of this study is to compare intensive and standard training for human insulin inhalation powder in patients with type 2 diabetes.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
97
Inclusion Criteria
  • Type 2 diabetes for at least 12 months
  • Age 18 or older.
  • Taking at least 1 oral antihyperglycemic medication.
  • Have an HbA1C between 7.5 and 12.
  • Be a nonsmoker
Exclusion Criteria
  • Body Mass Index (BMI) greater than 40.
  • Have frequent episodes of severe hypoglycemia.
  • Have advanced autonomic neuropathy.
  • Have history of asthma.
  • Have chronic obstructive pulmonary disease (COPD).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ALY041001 (HIIP)-
BLY041001 (HIIP)-
Primary Outcome Measures
NameTimeMethod
Hypothesis that std training for HIIP system is noninferior to intensive training by 1.2 mmol/L with respect to overall 2-hr postprandial glucose excursion of (SMBG) in type 2 diabetes patients that have been on preprandial trmt with HIIP4 weeks
Secondary Outcome Measures
NameTimeMethod
Assess the suitability of the HIIP delivery system for type 2 diabetes patients4 weeks
Compare the SMBG profiles of preprandial HIIP administration with standard training and with intensive training Assess patient compliance with the HIIP delivery system Directions for Use (DFU) provided by the Sponsor with and without intensive training4 weeks
Compare the test meal blood glucose profiles of preprandial HIIP administration with standard training and with intensive training4 weeks

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

🇿🇦

George, South Africa

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇿🇦George, South Africa
© Copyright 2025. All Rights Reserved by MedPath